Grifols's Subsidiary Biotest Forecasts Approximately $1B In Revenue From Sales In The U.S. Of Its Intravenous Immunoglobulin Yimmugo During The Next Seven Years, Following Recent FDA Approval To Treat Primary Immunodeficiencies
Grifols's Subsidiary Biotest Forecasts Approximately $1B In Revenue From Sales In The U.S. Of Its Intravenous Immunoglobulin Yimmugo During The Next Seven Years, Following Recent FDA Approval To Treat Primary Immunodeficiencies
基立福的子公司Biotest預計，在近7年內，其靜脈免疫球蛋白Yimmugo在美國銷售的營業收入將達到約10億美元，此前該產品已獲得FDA批准用於治療原發性免疫缺陷病。
- Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025
- 基立福集團旗下的Biotest公司預計將於2025年第一季度在美國推出其最近獲FDA批准的靜脈免疫球蛋白。
- Yimmugo will be distributed by Kedrion in the U.S. as part of a broader Group channel strategy, with Grifols focusing on continued growth of its current portfolio for this market
- Yimmugo將由Kedrion在美國分銷，作爲更廣泛集團渠道策略的一部分，而基立福則專注於繼續發展其當前市場的產品組合。
- It adds to Grifols' strong franchise of intravenous and subcutaneous immunoglobulins to meet growing patient demand for these therapeutics
- 這將增強基立福在靜脈和皮下免疫球蛋白領域的強勁知名度，以滿足不斷增長的患者對這些治療的需求。
- Yimmugo will be followed by other proteins in the pipeline, including fibrinogen and trimodulin, both in late-stage development
- Yimmugo將跟進其他正在研發中的蛋白質，包括晚期開發的纖維蛋白原和三聯素。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。